Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Asymptomatic Follicular Lymphoma (AFL) Trial: A Phase III Study of Single-Agent Rituximab Immunotherapy Versus Zevalin Radioimmunotherapy for Patients With New, Untreated Follicular Lymphoma Who Are Candidates for Observation

NCT02320292 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02320292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02320292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Asymptomatic Follicular Lymphoma (AFL) Trial: A Phase III Study of Single-Agent Rituximab Immunotherapy Versus Zevalin Radioimmunotherapy for Patients With New, Untreated Follicular Lymphoma Who Are Candidates for Observation
Lead sponsor
Mayo Clinic
Phase
Phase 3
Overall status
Terminated
Start date
February 11, 2015
Completion date
November 9, 2023
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage i grade 1 follicular lymphoma, ann arbor stage i grade 2 follicular lymphoma, ann arbor stage ii grade 1 contiguous follicular lymphoma, ann arbor stage ii grade 1 non-contiguous follicular lymphoma, ann arbor stage ii grade 2 contiguous follicular lymphoma, ann arbor stage ii grade 2 non-contiguous follicular lymphoma, ann arbor stage iii grade 1 follicular lymphoma, ann arbor stage iii grade 2 follicular lymphoma, ann arbor stage iv grade 1 follicular lymphoma, ann arbor stage iv grade 2 follicular lymphoma